Christopher Pierce
Keine laufenden Positionen mehr
Profil
Christopher Pierce worked as Senior Director-Hematologic Malignancies Portfolio at Pfizer Inc. from 2016 to 2017.
He then worked as Vice President & Head-Commercial at Loxo Oncology, Inc. from 2017 to 2019.
In 2019, he worked as Principal at Scout Advisers LLC.
In 2020, he worked as Chief Business Operations & Executive VP at Prelude Therapeutics, Inc. Mr. Pierce holds an MBA from Harvard Business School and an undergraduate degree from Harvard College.
Ehemalige bekannte Positionen von Christopher Pierce
| Unternehmen | Position | Ende |
|---|---|---|
| PRELUDE THERAPEUTICS INCORPORATED | Corporate Officer/Principal | 30.09.2021 |
| Scout Advisers LLC | Corporate Officer/Principal | 01.07.2020 |
| LOXO ONCOLOGY INC | Corporate Officer/Principal | 01.05.2019 |
| PFIZER, INC. | Corporate Officer/Principal | 01.03.2017 |
Ausbildung von Christopher Pierce
| Harvard Business School | Masters Business Admin |
| Harvard College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| PFIZER, INC. | Health Technology |
| PRELUDE THERAPEUTICS INCORPORATED | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Loxo Oncology, Inc.
 Loxo Oncology, Inc. Pharmaceuticals: MajorHealth Technology Loxo Oncology, Inc. is a biopharmaceutical company, which engages in the development of small molecule therapeutics for the treatment of cancer. It focuses on genetic alterations, targeted therapies, and genetic testing. The company was founded by Joshua H. Bilenker in May 2013 and is headquartered in Stamford, CT. | Health Technology |
| Scout Advisers LLC |
